Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

As adjuvant chemotherapy (AC) for soft tissue sarcomas is controversial, we performed a retrospective analysis of patients seen at Washington University in St. Louis to evaluate whether it benefited our patient population. Patients were risk-assessed using the Memorial Sloan Kettering Predictive Nom...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenone, Aaron D, Luo, Jingqin, Montgomery, Luke, Morgensztern, Daniel, Adkins, Douglas R, Van Tine, Brian A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101751/
https://www.ncbi.nlm.nih.gov/pubmed/24574357
http://dx.doi.org/10.1002/cam4.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101751/
https://www.ncbi.nlm.nih.gov/pubmed/24574357
http://dx.doi.org/10.1002/cam4.209

Ejemplares similares